Maze Therapeutics, Inc. · Brief

Next report

3 days

Nov 5 · after closeest.Q3 FY26

Earnings

Expected move

Inputs

±11.6%implied · report alone

27.8335.13

straddle ±14.6%

spot 31.48exp Nov 20ATM strike 30ATM straddle 5.40IV 89%

Oct 30 closereport share · term structure

Expected move

Inputs

Implied vs realized

7 reportsHistory

0 of 4≥ implied

avg implied: ±19.4%
avg realized: ±11.0%

Mar 31 '25—▼−3.59%—

May 14 '25—▲+2.10%—

Aug 12 '25—▼−1.02%—

Q3 FY25±14.2%▼−3.48%×0.25

Q1 FY26±38.2%▼−35.24%×0.92

May 12 '26±9.4%▲+4.58%×0.49

Q2 FY26±16.0%▲+0.81%×0.05

quarterimplied−40%0+40%realized×

Q2 FY26±16.0%▲+0.81%×0.05

May '26±9.4%▲+4.58%×0.49

Q1 FY26±38.2%▼−35.24%×0.92

Q3 FY25±14.2%▼−3.48%×0.25

Aug '25—▼−1.02%—

May '25—▲+2.10%—

Mar '25—▼−3.59%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2 of 4

4disclosed supplier and customer ties in SEC filingsSEC filings

0 of 20of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

Bear2

4 of 4recent reports where the move came in under the options-implied rangeEarnings history

24managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

MAZE report session

No linked exposure.

Latest changes

30 daysAll changes

Oct 22impliedImplied move: ±18.1% into Nov 5 earnings (Oct 22 close).Source

Oct 168-KMaterial agreement: 8-K Item 1.01.Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.